Using advanced imaging to predict the risk of blood clot recurrence in pulmonary embolism patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to identify the risk of venous thromboembolism recurrence in patients who have experienced a pulmonary embolism (PE) by utilizing Ventilation/Perfusion Single Photon Emission Computed Tomography (V/Q SPECT/CT) imaging. It focuses on patients classified as having an intermediate risk of recurrence, a group that has been less studied. By assessing residual pulmonary vascular obstruction (RPVO) through advanced imaging techniques, the study seeks to better stratify patients and determine who may benefit from prolonged anticoagulation therapy. The goal is to improve patient outcomes by identifying those at higher risk for recurrence who may require ongoing treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients ≥ 18 years,
* who experienced an objectively proven PE,
* who have been treated initially with anticoagulant therapy for 3 to 6 uninterrupted months (180 - 210 days) and for whom anticoagulation will not be prolonged.

Exclusion Criteria:

* Unwilling or unable to give written informed consent (protected adults, under tutorship or curatorship)
* Patients deprived of their liberty by a judicial or administrative decision, patients undergoing psychiatric care by virtue of Articles L. 3212-1 and L. 3213-1 who are not covered by the provisions of Article L. 1121-8 and patients admitted to a health or social establishment for purposes other than research
* No Social security affiliation
* Isolated DVT
* Pregnant women and parturients
* Other indication for anticoagulant therapy (e.g. atrial fibrillation, mechanic valve)
* Life expectancy \< 6 months
* Any patients for whom there is a strong indication to treat longer than 6 months:

  * PE provoked by a major persistent factor (e.g. cancer)
  * Recurrent unprovoked PE

PE provoked by a major transient risk factor (e.g. surgery with general anesthesia for greater than 30 min, confined to bed in hospital for at least 3 days with an acute illness, cesarean section)

AND none of the following persistent factors :

* BMI ≥ 30
* Chronic respiratory disease
* Chronic inflammatory disease (e.g., ulcerative colitis, rheumatoid arthritis, etc.)
* Hepatocellular insufficiency
* Renal insufficiency with creatinine clearance \< 60 mL/min
* Chronic or persistent immobilization

Where it's running

• CHU Amiens
  Amiens, France, France Recruiting
• CHU Brest
  Brest, France, France Recruiting
• Hôpital Louis MourierAP-HP
  Colombes, France, France Recruiting
• CHD Vendée - La Roche sur Yon
  La Roche-sur-Yon, France, France Recruiting
• CH Les Sables d'Olonne
  Les Sables-d'Olonne, France, France Recruiting
• Hegp Ap-Hp
  Paris, France, France Recruiting

Study contacts

• Study coordinator: Pierre-Yves LE ROUX, Pr
• Email: pierre-yves.leroux@chu-brest.fr
• Phone: +33298223327

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Prognostic value of the 2026 AHA/ACC PE classification in ED patients with acute PE

  This study tests whether the 2026 AHA/ACC five-category PE classification helps predict 30-day major adverse pulmonary embolism events in adults with acute PE presenting to the ED.

  Recruiting Marmara University Pendik Training and Research Hospital · Istanbul · NCT07805616

• Aspiration thrombectomy with the Symphony or Prodigy devices

  This project will try the Symphony and Prodigy aspiration thrombectomy devices to remove arterial, venous, or pulmonary blood clots in adults.

  Recruiting at 13 sites Imperative Care, Inc. · Huntsville, Alabama and 12 other locations · NCT07350499

• Timing of anticoagulation for preventing blood clots in patients with brain hemorrhage

  This study is testing whether starting blood-thinning treatment early or later can help prevent blood clots in patients with bleeding in the brain while keeping them safe from more bleeding.

  Recruiting Pirogov Russian National Research Medical University · Moscow · NCT06753786

• Personalized blood thinner treatment for hip and knee replacement patients

  This study is testing if personalized blood thinner treatments can better prevent blood clots and bleeding in patients getting hip or knee replacements compared to standard treatments.

  Recruiting at 12 sites Phase 4 Leiden University Medical Center · Apeldoorn, Gelderland and 12 other locations · NCT06581965

• Evaluating a new decision support tool for diagnosing blood clots

  This study is testing a new tool to help doctors diagnose blood clots in patients who might have conditions like pulmonary embolism or deep vein thrombosis, using fresh blood samples.

  Recruiting at 4 sites Diagnostica Stago R&D · Niort, Sartres and 3 other locations · NCT06480994

• Comparing rivaroxaban and low-molecular weight heparin for preventing blood clots in patients with lower limb trauma

  This study is testing if a new blood thinner called rivaroxaban can prevent blood clots better than a standard treatment in patients with leg injuries who are at high risk for clots.

  Recruiting at 26 sites Phase 3 University Hospital, Angers · Agen and 36 other locations · NCT06195540

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.